4D pharma's Blautix Phase II Clinical Trial Results Published in Alimentary Pharmacology & Therapeutics

4D pharma plc is a United Kingdom-based pharmaceutical company. The Company is focused on developing Live Biotherapeutic Products (LBPs), a class of drugs derived from the human gut microbiome. The Company's LBPs are biologics based on live organisms, namely single strains of bacteria. It has developed MicroRx, its LBP discovery platform. MicroRx interrogates its library of bacterial isolates for therapeutic functionality and characterizes the bacterial isolates using a range of complementary tools and technologies. Its microbiome profiling platform, MicroDx, analyses the microbiome to aid the diagnosis and treatment of patients with its Live Biotherapeutics. Its MicroRx platform has generated a pipeline of development programs in therapeutic areas, including immuno-oncology, gastrointestinal (GI), respiratory, autoimmune and central nervous system (CNS) diseases. Its MicroRx enables the discovery of MRx-4DP0004, which is engaged in an ongoing Phase I/II with partly controlled asthma.